Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

September 29, 2022

US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) to treat prurigo nodularis in adult patients.

US FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis